Clinical trials
Autistic Disorder trials in China with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
15 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 5 |
| Completed | 2 |
| Active, not recruiting | 2 |
| Unknown status | 2 |
| Enrolling by invitation | 1 |
| Terminated | 1 |
| Withdrawn | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Children's Hospital of Fudan University | 4 |
| University of Electronic Science and Technology of China | 3 |
| Arizona State University | 1 |
| Central South University | 1 |
| Chinese University of Hong Kong | 1 |
| First Affiliated Hospital Xi'an Jiaotong University | 1 |
| Hunan Normal University | 1 |
| Shanghai Mental Health Center | 1 |
| Xili Wen | 1 |
| Zeng Changhao | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Autistic Disorder | 15 |
| Autism Spectrum Disorder | 8 |
| Anorexia Nervosa | 1 |
| Communication Disorders | 1 |
| Gambling | 1 |
| Obesity | 1 |
| Obsessive-Compulsive Disorder | 1 |
| Parasomnias | 1 |
| Schizophrenia | 1 |
| Sleep Initiation and Maintenance Disorders | 1 |
Trials
Showing 1 to 15 of 15. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.